Rayence Co

Rayence Co FCF Growth

The Year-over-Year Free Cash Flow Growth of Rayence Co (228850.KQ) as of Nov 7, 2026 is -58.31 %. In the previous year, Year-over-Year Free Cash Flow Growth was -23.29 % — a change of 150.39% (lower).

FCF Growth

-58.31 %

YoY

150.39%

Last updated:

Year-over-Year Free Cash Flow Growth of Rayence Co is 2025 -58.31 % . Year-over-Year Free Cash Flow Growth of Rayence Co was 2024 -23.29 % . It decreases by 150.39% lower compared to the previous year.

The Rayence Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-23.13 KRW
Jan 1, 2019
-81.27 KRW
Jan 1, 2020
815.30 KRW
Jan 1, 2021
-8.35 KRW
Jan 1, 2022
-22.77 KRW
Jan 1, 2023
46.16 KRW
Jan 1, 2024
-23.29 KRW
Jan 1, 2025
-58.31 KRW
The Rayence Co FCF Growth history
YEARFCF GrowthYoY
-58.31 %+150.39%
-23.29 %-150.45%
46.16 %-302.71%
-22.77 %+172.66%
-8.35 %-101.02%
815.30 %-1,103.22%
-81.27 %+251.33%
-23.13 %-107.04%
328.71 %-148.47%
-678.14 %-54.20%
-1,480.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Year-over-Year Free Cash Flow Growth of Rayence Co is -58.31 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Rayence Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Rayence Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Rayence Co

All Key Metrics — Rayence Co